Pharmaceutical new product development: the increasing role of in-licensing.
Many pharmaceutical companies are facing a pipeline gap because of the increasing economic burden and uncertainty associated with internal research and development programs designed to develop new pharmaceutical products. To fill this pipeline gap, pharmaceutical companies are increasingly relying on in-licensing opportunities. New business development identifies new pharmaceuticals that satisfy unmet needs and are a good strategic fit for the company, completes valuation models and forecasts, evaluates the ability of the company to develop and launch products, and pursues in-licensing agreements for pharmaceuticals that cannot be developed internally on a timely basis. These agreements involve the transfer of access rights for patents, trademarks, or similar intellectual property from an outside company in exchange for payments. Despite the risks, in-licensing is increasingly becoming the preferred method for pharmaceutical companies with pipeline gaps to bring new pharmaceuticals to the clinician.
Edwards
Nancy V
NV
Goble and Associates, One East Wacker Drive, Suite 3200, Chicago, IL 60601, USA. nedwards@goble-assoc.com
D004341:Drug Evaluation / Q000379:methods; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000639:trends; D018973:Intellectual Property; D008004:Licensure / Q000639:trends; D040541:Marketing / Q000379:methods / Q000458:organization & administration / Q000639:trends; D009010:Monte Carlo Method; D016730:Program Development / Q000379:methods; D012106:Research